This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Welcome to edition 420 of Insider Weekends. Insider buying decreased last week with insiders purchasing $220.22 million of stock compared to $226.74 million in the week prior. Selling declined sharply with insiders selling $823.77 million of stock last week compared to $1.43 million in the week prior.
DDR XON RVI RVI.WI
Intrexon Corp. (NYSE:XON) has 183 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,162,559 shares. Largest shareholders include Third Security, LLC, Iridian Asset Management Llc/ct, Vanguard Group Inc, FMR LLC / Fidelity, Lmm Llc, State Street Corp, First Trust Advisors Lp, Morgan Stanley, BlackRock Inc.
STT STT.PRC XON STT.PRE STT.PRD STT.PRG MS.PRE VRX MS.PRF MS.PRG ISRG MS.PRA PGNX BLK MS.PRI BSX MS.PRK ICUI MS SLXP MZOR
EXTON, Pa., July 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 1,474,080 shares of its common stock which was priced at-the-market at a purchase price of $2.69 per share, for gross proceeds of approximately $3.
EXTON, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,474,080 shares of its common stock, at a purchase price per share of $2.
BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM).
ZIOP MKGAF XON MKGAY
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220326 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any
2018-06-04 - Asif
Overview The company believe Intrexon is a leader in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Synthetic biology involves the tightly controlled expression of natural and engineered genes (DNA segments) in a variety of animal, plant and microorganismal hosts. The company's historical approach primarily involved an exclusive channel collaboration, or ECC, model in which the company served principally as the technology engine for a partner experienced in a given commercial arena. As its experience has deepened, Intrexon has moved toward more joint ventures, or JVs, and the self-development of projects the company view as particularly compelling and within its increasing areas of expertise. Synthetic biology is a rapidly evolving discipline that applies engineering principles to biological systems to enable rational, design-based cont...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to XON / Intrexon Corp. on message board site Silicon Investor.
|The Exxon Free Environmental Thread||Exxon Mobil (XOM)|
|Intrexon XON||XON - Exxon Corp.|
|ExOne Inc.||MONE - MatrixOne|
|Axonyx Inc (AXYX)||LEXON INC. (LXXN:BB)|
|MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology||Axion Spatial Imaging Ltd. (AXON)|
as of ET